Cipla 的 plazomicin 获得 CDSCO 批准，这是一种治疗印度复杂尿路感染的新型抗生素。 Cipla receives CDSCO approval for plazomicin, a new antibiotic addressing complicated urinary tract infections in India.

Cipla 的 plazomicin 获得 CDSCO 批准，这是一种在印度治疗复杂尿路感染的新型抗生素，可解决抗菌素耐药性问题。 Cipla receives CDSCO approval for plazomicin, a new antibiotic treating complicated urinary tract infections in India, addressing antimicrobial resistance. Allecra Therapeutics 的抗生素 EXBLIFEP® 已获得 FDA 批准，用于治疗 18 岁以上成人的 cUTI，对抗革兰氏阴性菌的耐药性。 Allecra Therapeutics' antibiotic EXBLIFEP® is FDA-approved for treating cUTIs in adults aged 18+, combatting resistance in gram-negative bacteria. Orchid Pharma 的 Enmetazobactam 已获得 FDA 批准用于 cUTI 治疗，针对革兰氏阴性菌的抗菌耐药性。 Orchid Pharma's Enmetazobactam is approved by the FDA for cUTIs treatment, targeting anti-microbial resistance in gram-negative bacteria.